newsfilter
← Latest News
GlobeNewswire·

Genenta ASGCT Clinical Data Highlights Temferon™ Biological Effects in Glioblastoma

MILAN, Italy and NEW YORK, May 02, 2022 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ:GNTA), a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for cancer, announces that preliminar